Monil Shah

Monil Shah has a wealth of experience in the biotechnology and pharmaceutical sectors. Monil is currently the Managing Director at IAA Consulting LLC, a position they have held since January 2019. Monil has also served as the Chief Business Officer at Imugene Limited since June 2021, leading their business operations. Prior to this, they were the Head of Development at Stingray Therapeutics starting in January 2018. Monil held the role of Chief Development Officer at WindMIL Therapeutics from October 2018 to June 2021. Monil also served as a Scientific and Clinical Advisor at Brooklyn ImmunoTherapeutics from October 2017 to April 2021, and as their Chief Operating Officer from March 2017 to October 2018. Monil's experience includes working as the Global Medical Affairs Lead for Immuno-Oncology at Bristol-Myers Squibb from March 2014 to March 2017. Monil also held various positions at Ventrus Biosciences, Celgene, FibroGen, and Amgen, where they gained expertise in clinical research, development, and strategic planning.

Monil Shah completed their Doctorate of Pharmacy from Rutgers University between 1994 and 2000. Monil then pursued a Master in Business Administration with a focus on Healthcare Management from the Florida Institute of Technology, graduating between 2008 and 2012.